Neurotoxicity of commonly used antineoplastic agents (second of two parts).
about
Vincristine toxicity unrelated to dosePartially reversible nerve deafness due to vincristineLetter: neuropathy due to cytosine arabinosideIntestinal and liver toxicity of antineoplastic drugs.Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature.Measles inclusion-body encephalitis in a child with treated acute lymphoblastic leukaemiaPain and death: neurodegenerative disease mechanisms in the nociceptor.Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies.The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism.Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease.Successful treatment of a dog with massive 5-fluorouracil toxicosis.Craniocerebral involvement in lymphoma.Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy.Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.Late psychosocial effects of conditioning for BMT.Subacute sensory neuropathy with remission: an association with lymphoma.Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy
P2860
Q28320650-3536CCA0-AF67-4741-AAD9-9AA34189C4EEQ28331492-D20F92FC-BADE-4B45-B93C-D012DCC320F9Q28363203-20C25C4C-28ED-4B4E-9E34-1A3682A8F7B0Q33605823-684FF610-D38B-406B-8B3B-DC2726C80BBEQ35635738-DF80E0BD-FA51-42A2-B032-FF0392820DD4Q36602679-28316B97-D7AB-4222-8C95-96868E7F8FB8Q37833572-4FF6438E-156B-4EDA-8509-36F384C8E071Q38186752-6CEADAED-D69F-400B-89D4-BA4AC5251E55Q40204282-1AFE4AF5-BB00-4F43-95A1-21E26967BC59Q42670711-DFA465B5-30C0-4D3C-AC35-5BAB754BB957Q43424223-4263DF60-6CEA-44BE-AE0D-8312B2B2E12BQ44107912-980B6FDC-1877-4ABB-BDA4-81CAC9A1E39FQ44829827-C18238F3-197E-451E-8C77-945D6E56CC85Q48248977-BC6EA007-2D7C-4A81-891C-02BA3B16F8A9Q48732189-7F6043C5-03B2-4B46-B5E6-D793D17BA8B1Q52486105-D25BCD16-2F4C-4EFF-843B-9007AB7AD8B8Q53613106-9241DD1B-AC41-4EBB-A789-ACDEFD455C90Q55508887-61137AFF-1520-4A8B-8E89-5041E909D228Q56520646-900875BC-6121-4F14-9904-3087232FF0F7Q58771071-1E9AC050-E6DC-413D-A6A7-332777D7F255
P2860
Neurotoxicity of commonly used antineoplastic agents (second of two parts).
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年学术文章
@wuu
1974年学术文章
@zh-cn
1974年学术文章
@zh-hans
1974年学术文章
@zh-my
1974年学术文章
@zh-sg
1974年學術文章
@yue
1974年學術文章
@zh
1974年學術文章
@zh-hant
name
Neurotoxicity of commonly used antineoplastic agents (second of two parts).
@en
type
label
Neurotoxicity of commonly used antineoplastic agents (second of two parts).
@en
prefLabel
Neurotoxicity of commonly used antineoplastic agents (second of two parts).
@en
P2093
P1476
Neurotoxicity of commonly used antineoplastic agents (second of two parts).
@en
P2093
P304
P356
10.1056/NEJM197407182910305
P407
P577
1974-07-01T00:00:00Z